The cholesterol-lowering drug lovastatin corrects neurological phenotypes in animal models of fragile X syndrome (FX), a commonly identified genetic cause of autism and intellectual disability. The therapeutic efficacy of lovastatin is being tested in clinical trials for FX, however the structurally similar drug simvastatin has been proposed as an alternative due to an increased potency and brain penetrance. Here, we perform a side-by-side comparison of the effects of lovastatin and simvastatin treatment on two core phenotypes in the Fmr1 -/y mouse model. We find that while lovastatin normalizes excessive hippocampal protein synthesis and reduces audiogenic seizures (AGS) in the Fmr1 -/y mouse, simvastatin does not correct either phenotype. These results caution against the assumption that simvastatin is a valid alternative to lovastatin for the treatment of FX.
thorough AGS analysis using multiple doses of simvastatin and two different mouse strains. In all cases, simvastatin failed to reduce AGS in the Fmr1 -/y mouse, whereas lovastatin was significantly effective. This is compelling evidence that simvastatin may not be a suitable replacement for lovastatin with respect to the treatment of FX.
Materials and methods:
Mice: All mice were naive to drug and behavioral testing prior to experimentation. Mice were group housed with unrestricted food and water access and a 12h light-dark cycle. Room temperature was maintained at 21 ± 2°C. All procedures were performed in accordance with ARRIVE guidelines and regulations set by the University of Edinburgh and the UK Animals Act 1986. Fmr1 -/y mice (Jackson Labs 003025) were maintained on either a C57BL/6J (Charles River) or a mixed C57BL/6J x FVB background (C57BL/6J backcrossed to FVB by 2 generations).
Metabolic Labeling: Hippocampal slices were prepared from male littermate WT and Fmr1 -/y C57BL/6J mice (P25-32), in an interleaved fashion, with the experimenter blind to genotype as described previously [11] . Briefly, mice were anaesthetized with isoflurane and the hippocampus was rapidly dissected in ice-cold ACSF (124 mM NaCl, 3 mM KCl, 1.25 mM NaH 2 PO 4 , 26 mM NaHCO 3 , 10 mM dextrose, 1 mM MgCl 2 and 2 mM CaCl 2 , saturated with 95% O 2 and 5% CO 2 ). Slices (500 µm thick) were prepared using a Stoelting Tissue Slicer and transferred into 32.5°C ACSF (saturated with 95% O 2 and 5% CO 2 ) within 5 min. Slices were incubated in 32.5°C ACSF for 4 hr to allow for recovery of protein synthesis then transferred to ACSF containing 25 μM Actinomycin D (Tocris) plus either vehicle (0.05% DMSO in ddH 2 O), 50 μM lovastatin active form (CAS 75225-50-2; Calbiochem Merck Millipore), or 0.1-5 μM simvastatin active form (CAS 101314-97-0; Cayman Chemical) for 30 minutes. To measure new protein synthesis, slices were then transferred to fresh ACSF with 10 µCi/ml 35 S-Met/Cys (Perkin Elmer) containing vehicle or drug for another 30 min.
After labeling, slices were homogenized in ice-cold buffer (10 mM HEPES pH 7.4, 2 mM EDTA, 2 mM EGTA, 1% Triton X-100, protease inhibitors and phosphatase inhibitors) and incubated in trichloroacetic acid (TCA: 10% final) for 10 min on ice before being centrifuged at 16,000 rpm for 10 min. The pellet was washed in ice-cold ddH 2 O and resuspended in 1 N NaOH until dissolved, and the pH was re-adjusted to neutral using 0.33 N HCl. Triplicates of each sample were subjected to scintillation counting and protein concentration assay kit (BioRad). Counts per minute (CPM) were divided by protein concentration, and this was normalized to the CPM from the ACSF used for incubation. For display purposes, example slice homogenates were resolved on SDS-PAGE gels, transferred to nitrocellulose and exposed to a phosphorimaging screen (GE Healthcare). Phosphorimages were acquired using a Typhoon scanner (GE Healthcare) and compared to total protein staining of the same membrane.
Immunoblotting: Samples were resolved on SDS-PAGE gels, transferred to nitrocellulose and stained for total protein with the Memcode Reversible staining kit (Pierce). Membranes were later blocked with 5% BSA in TBS + 0.1% Tween-20 and incubated in primary antibody overnight at 4°C (Cell Signaling Technology: phospho-ERK1/2 (Thr202/Tyr204), 1:2000 (#9106), ERK1/2 1:2000 (#9102), phospho-p70S6K (Thr389) 1:1000 (#9234), p70S6K 1:1000 (#2708). Membranes were then washed, incubated with HRP-conjugated secondary antibodies for 30 min (Cell Signaling), and developed with Clarity ECL (BioRad). To compare phopho-to total for each target in the same lane, membranes developed for phospho (i.e., p-ERK1/2) were stripped and re-probed for total (i.e., ERK1/2). Densitometry was performed on scanned blot films using ImageStudio Lite software. Phosphorylation of target proteins was calculated as a ratio of phospho-to total. To correct for blot-to-blot variance, each signal was normalized to the average signal of all lanes on the same blot. All gels were loaded and analyzed by experimenter blind to genotype and treatment.
Audiogenic Seizures: Experiments were performed as previously described [15, 31] . Test cohorts were counterbalanced for genotype and treatment. Naive WT and Fmr1 -/y male P18-29 mice bred on a C57BL/6J or mixed C57BL/6J x FVB background were weighed and injected intraperitoneally (i.p.) with 3 mg/kg simvastatin prodrug (CAS 79902-63-9), 50 mg/kg simvastatin active form (CAS 101314-97-0), or 100 mg/kg lovastatin active form (CAS 75225-50-2) or respective vehicle (3, 20 , or 50 % DMSO + 10% Tween-80 in PBS). Animals were then transferred to a quiet (< 60 dB ambient sound) room for 1 hr. For testing, animals were moved to a transparent test chamber equipped with speakers and a webcam and allowed to habituate for 1 min. Audiogenic stimulation (recorded sampling of a modified personal alarm) was passed through an amplifier and 2 X 50-Watt speakers (KRK Rokit RP5 G3 Active Studio Monitor) to produce a stimulus of > 130 dB for 2 min. A decibel meter was placed at a standard distance from the speakers to ensure a stable emission of sound throughout each session. Incidence and severity of seizures was scored and video files for each session were saved. Stages of AGS severity were assigned according to previous work as follows: (1) wild running (WR; pronounced, undirected running and thrashing), (2) clonic seizure (violent spasms accompanied by loss of balance), or (3) tonic seizure (loss of movement and postural rigidity in limbs and tail). Any animal that reached tonic seizure was immediately humanely euthanized. All injections, testing and scoring was performed with the experimenter blind to genotype and treatment.
Statistics:
Statistical testing was performed using GraphPad Prism software. For biochemistry experiments, outliers > 2 SD from the mean were removed and significance determined by repeated measures two-way ANOVA and post hoc Sidak multiple comparisons test. For AGS experiments, significance was determined by Fisher's exact test. Results of all statistical analyses are reported in detail in the figure legends.
Results: Lovastatin, but not simvastatin, normalizes excessive protein synthesis in the Fmr1 -/y hippocampus.
In previous work we showed that lovastatin normalizes excessive protein synthesis in the Fmr1 -/y hippocampus through reduction of Ras-ERK1/2 activation, which corrects epileptogenic phenotypes [15] . To examine whether the same effect is seen with simvastatin, we utilized a metabolic labeling assay in hippocampal slices designed to assess protein synthesis in an intact preparation under physiological conditions [11] . Hippocampal slices were prepared from juvenile WT and Fmr1 -/y littermates, blind to genotype, and allowed to recover in oxygenating ACSF. Following this, slices were pre-incubated with Actinomycin D to block transcription, and new protein synthesis was labelled through incorporation of 35 Slabeled methionine/cysteine mix ( Figure 1A) .
Previous experiments tested a range of 10-50 µM lovastatin and showed that 50 µM was effective in normalizing protein synthesis in the Fmr1 -/y hippocampus [15] . To ensure that we could recapitulate these results, we measured protein synthesis in WT and Fmr1 -/y slices ± 50 µM lovastatin ( Figure 1B) . As expected, our experiments revealed a significant correction of excessive protein synthesis with lovastatin in the Fmr1 -/y mouse (WT veh = 100 ± 1.48%, WT lova = 100.06 ± 4.87%, KO veh = 117.97 ± 4.27%, KO lova = 106.04 ± 4.93%; WT vs KO veh p = 0.0032, KO veh vs lova p = 0.0368; n = 12). Next, we tested the efficacy of simvastatin using the same assay system. Based on the increased potency of simvastatin, and previous studies of simvastatin in neurons, we tested a range of 1-5 µM [32] [33] [34] . Interestingly, we find that simvastatin treatment not only fails to reduce protein synthesis in the Fmr1 -/y hippocampus, it causes a significant increase in both WT and Fmr1 -/y slices at 1-5 µM (WT vehicle = 100 ± 2.74%, WT 1 μM = 144.15 ± 14.96%, WT 5 μM = 146.47 ± 6.98%, KO vehicle = 110.60 ± 7.48%, KO 1 μM = 144.56 ± 13.05%, KO 5 μM = 154.90 ± 21.31%; WT veh vs 1μM p = 0.0371, WT veh vs 5 μM p = 0.0279, KO veh vs 5 μM p = 0.0364; n = 7) ( Figure 1C) .
This puzzling increase in protein synthesis led us to wonder whether a reduced concentration of simvastatin might be more appropriate. To test this, we exposed slices to vehicle or simvastatin at concentrations of 0.1-0.5 µM. Surprisingly, we find that even at these lower concentrations simvastatin causes a dose-dependent increase in protein synthesis, worsening the Fmr1 -/y phenotype (WT veh = 100 ± 2.21%, WT 0.1 μM = 106.99 ± 3.51%, WT 0.3 μM = 117.79 ± 4.08%, WT 0.5 μM = 124.13 ± 4.23%, KO veh = 115.61 ± 3.48%, KO 0.1 μM = 116.52 ± 2.21%, KO 0.3 μM = 129.15 ± 3.99%, KO 0.5 μM = 137.01 ± 3.08%; WT veh vs 0.3 μM p = 0.0002, WT veh vs 0.5 μM p < 0.0001, KO veh vs 0.3 μM p = 0.0035, KO veh vs 0.5 μM p < 0.0001; n = 9) ( Figure 1D) . These results show that unlike lovastatin, simvastatin does not correct excessive protein synthesis in the Fmr1 -/y hippocampus.
Lovastatin, but not simvastatin, reduces ERK1/2 activation.
Given the differential efficacy of lovastatin and simvastatin on excessive protein synthesis in the Fmr1 -/y , we wondered whether these compounds acted differently on translation control signaling pathways. Two major intracellular signaling pathways implicated in synaptic protein synthesis are the ERK1/2 pathway that stimulated translation initiation through eukaryotic initiation factor 4E (eIF4E), and the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway that activates p70 S6 kinase (p70S6K) to phosphorylate ribosomal protein S6 [35] (Figure 2A) . These two pathways lie downstream of the GTPases Ras and Rheb, both of which are regulated by farnesylation [36] . The reduced activation of Ras-ERK1/2 signaling upon lovastatin treatment has been documented in several contexts, including hippocampal slices [15, 17, 19, 20] . To confirm this, we incubated slices in vehicle or 50 µM lovastatin and performed quantitative immunoblotting for phosphorylated (p-) ERK1/2 (Figure 2B) . Our results confirm that 50 µM lovastatin significantly reduces p-ERK1/2 in Fmr1 -/y slices as previously reported (WT veh = 100 ± 4.32%, WT lova = 99.28 ± 4.42%, KO veh = 91.83 ± 4.74%, KO lova = 76.28 ± 3.76%; KO veh vs lova p = 0.0048; n =19). To examine whether simvastatin had a similar impact on ERK1/2 signaling, we performed the same immunoblotting analysis on slices exposed to vehicle or 0.1-0.5 µM simvastatin. In contrast to lovastatin, our results show that simvastatin has no significant impact on p-ERK1/2 in either WT or Fmr1 -/y slices at any dose tested (WT veh = 100 ± 4.51%, WT 0.1 μM = 102.87 ± 3.42%, WT 0.3 μM = 108.45 ± 4.10%, WT 0.5 μM = 101.01% ± 2.09%, KO veh = 105.63 ± 4.97%, KO 0.1 μM = 98.94 ± 4.46%, KO 0.3 μM = 94.71 ± 4.53%, KO 0.5 μM = 106.93 ± 3.65%; n = 11) ( Figure 2C) .
In addition to Ras, the farnesylation inhibition resulting from reduction of mevalonate upstream cholesterol has been reported to reduce the activation of Rheb [37, 38] . Although our previous study with lovastatin showed no effect of lovastatin on mTORC1 activation as assessed by phosphorylation of p70S6K, we wondered whether simvastatin had an observable impact on this pathway. To investigate, we immunoblotted for p-p70S6K in WT and Fmr1 -/y slices treated with 0.1-0.5 µM simvastatin. Our results show that p70S6K activation is unchanged in slices treated with 0.1-0.5 µM simvastatin (WT veh = 100 ± 11.14%, WT 0.1 μM = 112.94 ± 10.25%, WT 0.3 μM = 110.66 ± 9.47%, WT 0.5 μM = 98.89 ± 4.72%, KO veh = 92.87 ± 4.49%, KO 0.1 μM = 85.37% ± 11.82%, KO 0.3 μM = 101.71% ± 10.37%, KO 0.5 μM = 92.53% ± 10.64%; n = 10) ( Figure 2D) . These experiments show that unlike lovastatin, simvastatin does not suppress the activation of ERK1/2, and it has no effect on mTORC1 activation.
Lovastatin, but not simvastatin, corrects the AGS phenotype in the Fmr1 -/y mouse.
Our work in vitro shows that simvastatin does not correct the ERK1/2-stimulated excess in protein synthesis in the Fmr1 -/y hippocampus, suggesting that it may not have the same efficacy as lovastatin in ameliorating pathological phenotypes. To directly test this, we performed a side-by-side analysis of the effect of lovastatin versus simvastatin on the incidence of AGS in the Fmr1 -/y mouse. The AGS phenotype is one of the most robust behavioral phenotypes seen in the Fmr1 -/y mouse, and it models the epilepsy observed in FX patients [39, 40] . Several previous studies have used AGS as a benchmark for determining the efficacy of potential treatment strategies, consistently finding a positive correlation between treatment efficacy at reducing seizure incidence and correction of other pathologies [7, 11, 15, [41] [42] [43] .
In previous work, 1 mg/kg simvastatin was shown to sufficiently reduce epileptogenic activity and neurotoxicity in a kainic acid (KA) rat model of epilepsy [44] . This suggested simvastatin might be effective in reducing AGS in the Fmr1 -/y mouse even when protein synthesis is not normalized. To investigate, we tested the effect of 3 mg/kg simvastatin on AGS incidence and severity in Fmr1 -/y and littermate WT mice bred on a C57BL/6J background as described in Materials and Methods. Animals were injected with vehicle or simvastatin with the experimenter blind to genotype and treatment, and then left in a quiet environment for 1 hour. To induce AGS, animals were transferred to a test chamber and exposed to a 2-minute digitized sampling of a personal alarm passed through 50-Watt speakers a level of greater than 130 decibels. Seizures were recorded at increasing levels of severity as: 1 -wild running (uncontrolled and undirected running), 2 -clonic seizure (loss of balance with violent spasms on all limbs), and 3 -tonic seizure (loss of balance with postural rigidity in limbs and tail) ( Figure 3A) .
Our results show that vehicle treated Fmr1 -/y mice exhibit a higher incidence of AGS versus WT littermates (WT veh 4%, KO veh 30%; WT vs KO veh p = 0.0279). However, in contrast to our previous work with lovastatin, we found that simvastatin injection had no significant effect on the incidence of AGS in Fmr1 -/y mice (WT simva 0%, KO simva 22%; WT vs KO simva p = 0.0250, KO veh vs simva p = 0.7570), nor did it reduce AGS severity (KO veh: wild running 5/27, clonic 3/27, tonic 0/27; KO simva: wild running 2/27, clonic 4/27, tonic 0/27) (Figure 3B) . Although the AGS phenotype is seen in Fmr1 -/y mice bred on multiple mouse background strains, the FVB background strain exhibits a higher incidence of AGS that persists into adulthood [41, 45] . To ensure that the failure to observe a reduction of seizures with simvastatin was not due to a mouse strain-dependent effect, we performed additional AGS experiments using Fmr1 -/y C57BL/6J mice backcrossed two generations to FVB. Consistent with other studies, we found that vehicle treated Fmr1 -/y mice showed a higher incidence of AGS with introduction of the FVB strain (Figure 3C) [41, 45] . However, 3 mg/kg simvastatin remained ineffective in reducing the AGS phenotype in Fmr1 -/y mice even on the C57BL/6J x FVB background (WT veh 8%, WT simva 9%, KO veh 75%, KO simva 75%; WT vs KO veh p = 0.0028, WT vs KO simva p = 0.0028, KO veh vs simva p = 1.000). AGS severity was also not reduced by simvastatin (KO veh: wild running 1/12, clonic 5/12, tonic 3/12; KO simva: wild running 3/12, clonic 2/12, tonic 4/12) (Figure 3C) . Hence, 3 mg/kg simvastatin does not correct the AGS phenotype in Fmr1 -/y mice on either background strain.
A broad range of simvastatin doses has been used to examine the potential impact on KA-induced seizures and other neurological phenotypes in mice, with the 50 mg/kg being the highest dose tested [46, 47] . An equipotent 100 mg/kg dose of lovastatin was previously shown to correct AGS in adult Fmr1 -/y FVB mice, and we wondered whether the higher 50 mg/kg dose of simvastatin would be similarly effective [15] . Additional AGS experiments were performed on Fmr1 -/y and WT C57BL/6J x FVB mice injected with vehicle or 50 mg/kg simvastatin. To ensure a maximal potency, we injected the active form of simvastatin that does not require hydrolyzation from a prodrug form [25] . Our results show that even at this higher dose, simvastatin does not reduce AGS incidence in Fmr1 -/y mice (WT veh 8%, WT simva 8%, KO veh 64%, KO simva 55%; WT vs KO veh p = 0.0053, WT vs KO simva p = 0.0233, KO veh vs simva p = 0.6968), nor does it reduce AGS severity (KO veh: wild running 0/14, clonic 1/14, tonic 8/14; KO simva: wild running 0/11, clonic 3/11, tonic 3/11) (Figure 3D) . In contrast, Fmr1 -/y C57BL/6J x FVB mice injected with 100 mg/kg lovastatin showed a significant reduction in AGS versus vehicle-treated mice (WT veh 13%, WT lova 12%, KO veh 69%, KO lova 21%; WT vs KO veh p = 0.0032, KO veh vs lova p = 0.0136, WT veh vs KO lova p = 0.6513) (Figure 3E) . Together, these results show that lovastatin, not simvastatin, is effective in ameliorating AGS in the Fmr1 -/y model.
Discussion:
The promising results using lovastatin in FX have led to the suggestion that simvastatin may be similarly effective. In this study, we performed a thorough analysis of two core phenotypes in the Fmr1 -/y mouse model to test the prediction that simvastatin can be used in place of lovastatin. Our results show that simvastatin not only fails to correct excessive protein synthesis in the Fmr1 -/y hippocampus, it worsens this phenotype (Figure 1) . Moreover, simvastatin does not reduce ERK1/2 activation in the Fmr1 -/y hippocampus, suggesting it does not share the same mechanism as lovastatin in reducing Ras activity (Figure 2) . Importantly, analysis of the AGS phenotype in the Fmr1 -/y mouse shows that simvastatin does not reduce seizures in either of the two mouse strains tested, even at high doses (Figure 3) . Together, these results suggest that simvastatin is not an effective replacement for lovastatin with respect to the treatment of FX.
Although we propose the beneficial effect of lovastatin stems from the inhibition of ERK1/2-driven protein synthesis, it is important to note that statins are capable of affecting several biochemical pathways. Beyond the canonical impact on cholesterol biosynthesis, statins also decrease isoprenoid intermediates including farnesyl and geranylgeranyl pyrophosphates that regulate membrane association for many proteins including the small GTPases Ras, Rho and Rac [18, 46, 48, 49] . The increase in protein synthesis seen with simvastatin could be linked to altered posttranslational modification of these or other proteins. Indeed, although we see no change in mTORC1-p70S6K signaling, other studies have shown an activation of the PI3 kinase pathway that could be contributing to this effect [32] . However, our comparison of lovastatin and simvastatin shows that there is a clear difference in the correction of pathology in the Fmr1 -/y model, suggesting that the impact on ERK1/2 is an important factor in terms of pharmacological treatment for FX.
There are many reasons why statins would be an attractive option for treating neurodevelopmental disorders such as FX. They are widely prescribed worldwide for the treatment of hypercholesterolemia and coronary heart disease [50] , and safely used for longterm treatment in children and adults [46] . However, our study suggests that care should be taken when considering which statin should be trialed for the treatment of FX and other disorders of excess Ras. Although the effect of different statins on cholesterol synthesis has been well documented, the differential impact on Ras-ERK1/2 signaling is not well established. We show here that, contrary to lovastatin, simvastatin fails to inhibit the Ras-ERK1/2 pathway in the Fmr1 -/y hippocampus, exacerbates the already elevated protein synthesis phenotype, and does not correct the AGS phenotype. These results are significant for considering future clinical trials with lovastatin or simvastatin for FX or other disorders of excess Ras. Indeed, clinical trials using simvastatin for the treatment of NF1 have shown little promise, while trials with lovastatin show an improvement in cognitive deficits [28] [29] [30] . We suggest that simvastatin could be similarly ineffective in FX and may not be a suitable substitute for lovastatin in further clinical trials. Lovastatin significantly decreases protein synthesis in Fmr1 -/y slices to WT levels (WT vehicle = 100 ± 1.48%, WT lova = 100.06 ± 4.87%, KO vehicle = 117.97 ± 4.27%, KO lova = 106.04 ± 4.93%; ANOVA genotype *p = 0.0106; Sidak WT veh vs KO veh *p= 0.0032, WT lova vs KO lova p = 0.3516, KO veh vs KO lova *p = 0.0368; n = 12). (C) Simvastatin raises protein synthesis in both WT and Fmr1 -/y slices at 1-5 μM (WT vehicle = 100 ± 2.74%, WT 1 μM = 144.15 ± 14.96%, WT 5 μM = 146.47 ± 6.98%, KO vehicle = 110.60 ± 7.48%, KO 1 μM = 144.56 ± 13.05%, KO 5 μM = 154.90 ± 21.31%; ANOVA treatment *p = 0.0125; Sidak WT veh vs 1μM *p = 0.0371, WT veh vs 5 μM *p = 0.0279, KO veh versus 5 μM *p = 0.0364; n = 7). (D) Simvastatin raises protein synthesis at 0.1-0.5 μM, exaggerating the excessive protein synthesis phenotype (WT vehicle = 100 ± 2.21%, WT 0.1 μM = 106.99 ± 3.51%, WT 0.3 μM = 117.79 ± 4.08%, WT 0.5 μM = 124.13 ± 4.23%, KO vehicle = 115.61 ± 3.48%, KO 0.1 μM = 116.52 ± 2.21%, KO 0.3 μM = 129.15 ± 3.99%, KO 0.5 μM = 137.01 ± 3.08%; ANOVA treatment *p < 0.0001, genotype *p = 0.0068; Sidak WT veh vs 0.3 μM *p = 0.0002, WT veh vs 0.5 μM *p < 0.0001, KO veh vs 0.3 μM *p = 0.0035, KO veh vs 0.5 μM *p < 0.0001, WT veh vs KO veh *p = 0.0005, WT 0.1μM vs KO 0.1μM *p = 0.0406, WT 0.3 μM vs KO 0.3μM *p = 0.0115, WT 0.5 μM vs KO 0.5 μM *p = 0.0038; n = 9). Representative samples were run on SDS PAGE gels and transferred to membranes. Example phosphorimages of 35 slices incubated with 50 µM lovastatin show a significant reduction in ERK1/2 phosphorylation (WT vehicle = 100 ± 4.32%, WT lova = 99.28 ± 4.42%, KO vehicle = 91.83 ± 4.74%, KO lova = 76.28 ± 3.76%; ANOVA genotype *p = 0.0146; Sidak KO veh vs KO lova *p = 0.0048; n = 19). (C) Simvastatin treatment does not reduce ERK1/2 phosphorylation in Fmr1 -/y or WT slices (WT vehicle = 100 ± 4.51%, WT 0.1 μM = 102.87 ± 3.42%, WT 0.3 μM = 108.45 ± 4.10%, WT 0.5 μM = 101.01 ± 2.09%, KO vehicle = 105.63 ± 4.97%, KO 0.1 μM = 98.94 ± 4.46%, KO 0.3 μM = 94.71 ± 4.53%, KO 0.5 μM = 106.93 ± 3.65%; ANOVA treatment p = 0.8761, genotype p = 0.7010; n = 11). (D) Simvastatin treatment does not reduce phosphorylation of p70S6K in WT or Fmr1 -/y slices (WT vehicle = 100 ± 11.14%, WT 0.1 μM = 112.94 ± 10.25%, WT 0.3 μM = 110.66 ± 9.47%, WT 0.5 μM = 98.89 ± 4.72%, KO vehicle = 92.87 ± 4.49%, KO 0.1 μM = 85.37 ± 11.82%, KO 0.3 μM = 101.71 ± 10.37%, KO 0.5 μM = 92.53 ± 10.64%; ANOVA treatment p = 0.6206, genotype p = 0.2860, n = 10). Representative bands were cropped from original blots as indicated by blank spaces. Error bars = SEM. N = littermate pairs. Schematic shows the experimental timeline and scoring system for AGS testing. (B) Injection of 3 mg/kg simvastatin does not reduce AGS incidence in Fmr1 -/y mice bred on a C57BL/6J background (WT veh 4%, WT simva 0%, KO veh 30%, KO simva 22%; Fisher's exact test WT vs KO veh *p = 0.0279, WT vs KO simva *p = 0.0250, KO veh vs simva p = 0.7570). AGS severity is also not reduced (KO veh: wild running 5/27, clonic 3/27, tonic 0/27; KO simva: wild running 2/27, clonic 4/27, tonic 0/27). (C) 3 mg/kg simvastatin does not reduce incidence of AGS in Fmr1 -/y mice bred on a C57BL/6J x FVB background (WT veh 8%, WT simva 9%, KO veh 75%, KO simva 75%; Fisher's exact test WT vs KO veh *p = 0.0028, WT
